TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling

Mark A. Lomaga, Wen-Chen Yeh, Ildiko Sarosi, Gordon S. Duncan, Caren Furlonger, Alexandra Ho, Sean Morony, Casey Capparelli, Gwyneth Van, Stephen Kaufman, Annette van der Heiden, Annick Itie, Andrew Wakeham, Wilson Khoo, Takehiko Sasaki, Zhaodan Cao, Josef M. Penninger, Christopher J. Paige, David L. Lacey, Colin R. Dunstan, William J. Boyle, David V. Goeddel, and Tak W. Mak Department of Pharmaceutical Sciences, Faculty of Pharmacy, University of Toronto, Toronto, Ontario, Canada M5S 2S2; Amgen Institute, Ontario Cancer Institute and University of Toronto, Toronto, Ontario, Canada M5G 2C1; Amgen, Inc., Thousand Oaks, California 91320-1789 USA; Departments of Medical Biophysics and Immunology, University of Toronto and Ontario Cancer Institute, Toronto, Ontario, Canada M5G 2M9; Tularik, Inc., South San Francisco, California 94080 USA